Molecular-Targeted Agents in Pancreatic Cancer

Cancer Control

Volumn 11, Issue 1, 2004, Pages 32-38

  Saad, Everardo D ^a   Hoff, Paulo M ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BEVACIZUMAB; BILIRUBIN; CA 19-9 ANTIGEN; CELECOXIB; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; GELATINASE A; GELATINASE B; GEMCITABINE; LONAFARNIB; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; PLACEBO; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; TANOMASTAT; TIPIFARNIB; TRASTUZUMAB; VASCULOTROPIN ANTIBODY;

ADVANCED CANCER; ALLERGIC REACTION; ASTHENIA; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DIARRHEA; DRUG ABSORPTION; DRUG HALF LIFE; DRUG TARGETING; EXTRACELLULAR MATRIX; FATIGUE; FEVER; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; LIVER DYSFUNCTION; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; ONCOGENE H RAS; ONCOGENE K RAS; ONCOGENE N RAS; ONCOGENE NEU; PANCREAS CANCER; PROGNOSIS; RASH; REVIEW; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 2342622567     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480401100105     Document Type: Review

References (69)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
3. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 2002;20:3270-3275.
4. Bramhall SR, Rosemurgy A, Brown PD, et al. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol. 2001;19:3447-3455.
5. Bramhall SR, Schulz J, Nemunaitis J, et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87:161-167.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
7. Jones L, Ghaneh P, Humphreys M, et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci. 1999;880:288-307.
8. Bramhall SR, Neoptolemos JP, Stamp GW, et al. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. J Pathol. 1997;182:347-355.
9. Koshiba T, Hosotani R, Wada M, et al. Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer. 1998;82:642-650.
10. Hidalgo M, Eckhardt SG. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst. 2001;93:178-193.
11. Wojtowicz-Praga S, Torri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol. 1998;16:2150-2156.
12. Rosemurgy A, Harris J, Langleben A, et al. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am J Clin Oncol. 1999;22:247-252.
13. Evans JD, Stark A, Johnson CD, et al. A phase II trial of marimastat in advanced pancreatic cancer. Br J Cancer. 2001;85:1865-1870.
14. Moore M, Hamm J, Eisenberg P, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2000;930. Abstract.
15. Hess KR, Abbruzzese JL. Matrix metalloproteinase inhibition of pancreatic cancer: matching mechanism of action to clinical trial design. J Clin Oncol. 2001;19:3445-3446.
16. Barbacid M. Ras genes. Annu Rev Biochem. 1987;56:779-827.
17. Longnecker DS, Terhune PG. What is the true rate of K-ras mutation in carcinoma of the pancreas? Pancreas. 1998;17:323-324.
18. End DW, Smets G, Todd AV, et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 2001;61:131-137.
19. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001;61:8758-8768.
20. Hudes GR, Schol J, Baab J, et al. Phase I clinical and pharmacokinetic trial of the farnesyltransferase inhibitor R115777 on a 21-day dosing schedule. Proc Annu Meet Am Soc Clin Oncol. 1999;601. Abstract.
21. Zujewski J, Horak ID, Bol CJ, et al. Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol. 2000;18:927-941.
22. Karp JE, Lancet JE, Kaufmann SH, et al. Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood. 2001;97:3361-3369.
23. Punt CJ, van Maanen L, Bol CJ, et al. Phase I and pharmacokinetic study of the orally administered farnesyl transferase inhibitor R115777 in patients with advanced solid tumors. Anticancer Drugs. 2001;12:193-197.
24. Adjei AA, Erlichman C, Davis JN, et al. A phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000;60:1871-1877.
25. Macdonald JS, Chansky K, Whitehead R, et al. A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest Oncology Group (SWOG) study. Proc Annu Meet Am Soc Clin Oncol. 2002;548. Abstract.
26. Cohen SJ, Ho L, Ranganathan S, et al. Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol. 2003;21:1301-1306.
27. Patnaik A, Eckhardt S, Izbicka E, et al. A phase I and pharmacokinetic (PK) study of the farnesyltransferase inhibitor, R115777 in combination with gemcitabine (Gem). Proc Annu Meet Am Soc Clin Oncol. 2000;5A. Abstract.
28. Van Cutsem E, Karasek P, Oettle H, et al. Phase III trial comparing gemcitabine + R115777 (Zarnestra) versus gemcitabine + placebo in advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2002;A517.
29. Johnston SR, Hickish T, Ellis P, et al. Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol. 2003;21:2492-2499.
30. Cortes J, Albitar M, Thomas D, et al. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood. 2003;101:1692-1697.
31. Kurzrock R, Kantarjian HM, Cortes JE, et al. Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase I setting. Blood. 2003;102:4527-4534.
32. Willett CG, Safran H, Abrams RA, et al. Clinical research in pancreatic cancer: the Radiation Therapy Oncology Group trials. Int J Radiat Oncol Biol Phys. 2003;56:31-37.
33. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clin Oncol. 2001;19:32S-40S.
34. Abbruzzese JL, Rosenberg A, Xiong Q, et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients with advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2001;518. Abstract.
35. Mendelsohn J. The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer. 2001;8:3-9.
36. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res. 2000;6:1936-1948.
37. Yamanaka Y, Friess H, Kobrin MS, et al. Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol. 1993;24:1127-1134.
38. Safran H, King T, Steinhoff M, et al. Her-2/neu overexpression in pancreatic adenocarcinoma. Proc Annu Meet Am Soc Clin Oncol. 2000;1251. Abstract.
39. Safran H, Ramanathan RK, Schwartz J, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Annu Meet Am Soc Clin Oncol. 2001;517. Abstract.
40. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002;1:117-123.
41. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 2002;20:4292-4302.
42. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002;20:3815-3825.
43. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 2001;19:3267-3279.
44. Kris MG, Natale R, Herbst RS, et al. A phase II trial of ZD1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc Annu Meet Am Soc Clin Oncol. 2002; 1166. Abstract.
45. Dragovich T, Patnaik A, Rowinsky EK, et al. A phase I B trial of gemcitabine and erlotinib HCL in patients with advanced pancreatic adenocarcinoma and other potentially responsive malignancies. Proc Annu Meet Am Soc Clin Oncol. 2003;895. Abstract.
46. Giaccone G. A phase III clinical trial of ZD1839 ("Iressa") in combination with gemcitabine and cisplatin in chemotherapynaive patients with advanced non-small-cell lung cancer (INTACT 1). Ann Oncol. 2002;13:2,A4.
47. Johnson D. ZD1839 ("Iressa") in combination with paclitaxel and carboplatin in chemotherapy-naive patients with advanced non-small-cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol. 2002;13:127,A486.
48. Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
49. Itakura J, Ishiwata T, Friess H, et al. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res. 1997;3:1309-1316.
50. Ikeda N, Adachi M, Taki T, et al. Prognostic significance of angiogenesis in human pancreatic cancer. Br J Cancer. 1999;79:1553-1563.
51. Seo Y, Baba H, Fukuda T, et al. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000;88:2239-2245.
52. Itakura J, Ishiwata T, Shen B, et al. Concomitant over-expression of vascular endothelial growth factor and its receptors in pancreatic cancer. Int J Cancer. 2000;85:27-34.
53. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol. 2001;19:843-850.
54. Margolin K, Gordon MS, Holmgren E, et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol. 2001;19:851-856.
55. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21:60-65.
56. Hurwitz H, Fehrenbacher L, Cartwright T, et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc Annu Meet Am Soc Clin Oncol. 2003;3646. Abstract.
57. Kindler HLAR, Lester E, et al. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC). Proc Annu Meet Am Soc Clin Oncol. 2003;1037. Abstract.
58. Molina MA, Sitja-Arnau M, Lemoine MG, et al. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999;59:4356-4362.
59. Okami J, Yamamoto H, Fujiwara Y, et al. Overexpression of cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res. 1999;5:2018-2024.
60. Eibl G, Reber HA, Wente MN, et al. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas. 2003;26:33-41.
61. Xiong HQ, Du M, Wolff RA, et al. Pharmacology study of celecoxib in combination with gemcitabine for advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2002;448. Abstract.
62. Smith SE, Burris HA, Loehrer PJ, et al. Preliminary report of a phase II trial of gemcitabine combined with celecoxib for advanced pancreatic cancer. Proc Annu Meet Am Soc Clin Oncol. 2003;1502. Abstract.
63. Tong WG, Ding XZ, Witt RC, et al. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther. 2002;1:929-935.
64. Kaufman HL, Di Vito J Jr, Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am. 2002;16:159-197.
65. Gjertsen MK, Buanes T, Rosseland AR, et al. Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: clinical and immunological responses in patients with pancreatic adenocarcinoma. Int J Cancer. 2001;92:441-450.
66. Brett BT, Smith SC, Bouvier CV, et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J Clin Oncol. 2002;20:4225-4231.
67. Jaffee EM, Hruban RH, Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001;19:145-156.
68. Schnurr M, Galambos P, Scholz C, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines. Cancer Res. 2001;61:6445-6450.
69. Greten TF, Jaffee EM. Cancer vaccines. J Clin Oncol. 1999;17:1047-1060.